April 2026
Hormone replacement therapy (HRT) is one of the most effective treatments for managing menopausal symptoms in postmenopausal women, including vasomotor symptoms (hot flashes and night sweats), sleep disturbances, mood changes, and genitourinary issues. Estrogen can be delivered through oral tablets or topical/transdermal routes such as creams, gels, patches, and sprays. Oral estrogen undergoes first-pass metabolism in the liver, which can amplify certain effects and risks. Topical and transdermal estrogen enter the bloodstream directly through the skin, largely bypassing the liver and potentially offering a more favorable safety profile.4
This article examines the comparative evidence on effectiveness, safety, and clinical outcomes between topical/transdermal estrogen and oral estrogen, drawing from meta-analyses, observational studies, and systematic reviews.
Effectiveness for Symptom Relief
Safety Profile: Venous Thromboembolism (VTE) Risk
The most clinically important difference is the risk of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. Oral estrogen increases clotting factors through its hepatic first-pass effect, while transdermal estrogen has minimal impact on these factors.
A 2019 BMJ nested case-control study involving over 80,000 women found that oral HRT was associated with a significantly increased VTE risk (adjusted odds ratio 1.58) compared with no exposure, while transdermal HRT showed no increased risk (adjusted odds ratio 0.93).
When directly compared, oral HRT carried approximately 70% higher VTE risk than transdermal HRT.3
An updated 2018 meta-analysis reported that among women using estrogen-only preparations, oral estrogen raised VTE risk (relative risk 1.48), while transdermal estrogen did not (relative risk 0.97).1 A 2010 meta-analysis similarly showed pooled risk ratios of 1.9 for oral estrogen users versus 1.0 for transdermal users.5 These findings are consistent across observational studies, and transdermal estrogen does not appear to increase recurrent VTE risk even in women with a prior history.11
Cardiovascular and Lipid Effects
Oral estrogen produces more pronounced changes in lipid profiles, including greater increases in high-density lipoprotein (HDL) cholesterol but also significantly higher triglycerides. Transdermal estrogen has a more neutral effect on triglycerides and avoids inducing procoagulant changes in the liver. Evidence on broader cardiovascular events is mixed, but many analyses favor transdermal routes in women with higher baseline risk.6
Bone Health Benefits
Both routes support bone mineral density (BMD) and help prevent osteoporosis. A 2017 meta-analysis of clinical trials showed that transdermal estrogen increased lumbar spine BMD by 3.4% after one year and 3.7% after two years compared to baseline.11 Benefits are comparable to oral forms when dosed appropriately.
Mental Health and Quality of Life
Emerging data suggest potential advantages for transdermal estrogen in mental health outcomes. A 2025 retrospective study of over 3,800 postmenopausal women found transdermal HRT associated with a lower incidence of anxiety (7.2% vs. 9.1%) and depression (3.3% vs. 5.1%) compared with oral HRT. Both routes improve overall quality of life through symptom relief.12
Compounded Topical Options: The Case for BiEST
Compounded bioidentical estrogen creams, such as Biest (a mixture of estriol and estradiol, commonly in 80:20 or 50:50 ratios), are a popular topical option for customized dosing and affordability. A 2013 randomized clinical trial comparing compounded Biest cream to a standard estradiol patch found that the compounded cream produced significantly lower serum estradiol levels at typical doses (AUC-estradiol of 181 vs. 956 for the 2.0 mg dose, p < 0.001).7 Another study confirmed lower estrogen exposure from compounded transdermal estradiol creams compared to FDA-approved patches and gels.8
While compounded topical formulations still benefit from bypassing first-pass liver metabolism, patients may require careful monitoring and individualized dosing adjustments.
Guidelines and Clinical Recommendations
Major guidelines emphasize individualized therapy. The 2022 North American Menopause Society (NAMS) Position Statement highlights that hormone therapy is most effective for vasomotor symptoms and bone protection, with transdermal routes potentially decreasing risks of VTE and stroke in appropriate candidates. Benefits generally outweigh risks for healthy women under age 60 or within 10 years of menopause onset when using the lowest effective dose for the shortest duration necessary.10
Clinicians should consider patient-specific factors such as VTE history, obesity, smoking status, or thrombophilia when choosing the route of administration, with periodic reevaluation of benefits and risks.
Conclusion
Current evidence indicates that topical and transdermal estrogen provide comparable effectiveness to oral estrogen for relieving menopausal symptoms and supporting bone health, while offering a superior safety profile—particularly with respect to VTE risk. By avoiding first-pass liver metabolism, transdermal routes reduce elevations in clotting factors and triglycerides associated with oral forms.
For many women, especially those with elevated thrombotic or cardiovascular risk factors, transdermal options (including patches, gels, creams, and compounded formulations such as Biest) represent a well-supported choice. Shared decision-making between patient and provider is critical, taking into account personal medical history, preferences, and regular monitoring. Ongoing research continues to refine our understanding of optimal dosing and long-term outcomes across different delivery methods.
Key differences between oral and transdermal estrogen therapy:
| Category | Oral Estrogen | Topical / Transdermal Estrogen |
|---|---|---|
| Hormone Levels | More variable peaks and troughs | More stable serum levels |
| Formulations | Tablets | Patches, gels, creams, sprays, compounded options (e.g., Biest) |
| Best Fit Patients | Lower VTE risk, prefers oral dosing | Higher VTE/CV risk, prefers steady delivery or non-oral route |
References
- Scarabin PY. Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis. Climacteric. 2018;21(4):341-345.
- Abdelrazeq SY, et al. Comparative Evidence Between Transdermal and Oral Menopausal Hormone Therapy. Canadian Journal of Health Technologies. 2025.
- Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies. BMJ. 2019;364:k4810.
- American College of Obstetricians and Gynecologists. Postmenopausal Estrogen Therapy: Route of Administration and Risk of Venous Thromboembolism. Committee Opinion. 2013 (reaffirmed).
- Olié V, et al. Risk of venous thrombosis with oral versus transdermal estrogen therapy. Curr Opin Obstet Gynecol. 2010.
- Mohammed K, et al. Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015.
- Sood R, et al. Bioidentical compounded hormones: A pharmacokinetic evaluation in a randomized clinical trial. Maturitas. 2013.
- Newman MS, et al. Comparative estrogen exposure from compounded transdermal estradiol creams vs FDA-approved products. 2023.
- Najeeb S, et al. Comparative Evidence Between Transdermal and Oral Estrogen. 2025.
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022.
- Abdi F, et al. The Effects of Transdermal Estrogen Delivery on Bone Mineral Density in Postmenopausal Women: A Meta-analysis. Iran J Pharm Res. 2017.
- The Menopause Society. Oral or Transdermal Hormone Therapy? The Mental Health Risks Are Not the Same. Press release, 2025.